ClearNote Health closes $52M Series D for early cancer detection
What's the deal? ClearNote Health, a company building blood-based early cancer detection tools, has closed a $52M Series D round. The financing brings total funding to more than $185M. Alongside the raise, the company appointed Kevin Keegan — a diagnostics veteran with nearly 30 years of experience at BD, Illumina, and Hologic — as president and chief operating officer.
The round was led by founding investor Mattias WestmanDealroom has a profile for this one. Try Dealroom → and a large, long-only active manager. Other participants included former Citigroup chief executive officer Sandy Weill, co-founder Dr. Stephen Quake of Stanford University, a Seattle-based family office, and other institutional investors.
Proceeds will fund commercial expansion, clinical studies, product development, and broader global access to ClearNote Health's Avantect early cancer detection tests and its Virtuoso epigenomic drug development platform.
Why now? The company is riding momentum from the recent launch of its enhanced Avantect Pancreatic Cancer Test — a blood-based screening tool that uses a multiomic approach and machine learning to identify early-stage cancers. Demand for noninvasive, affordable cancer detection is growing, and ClearNote Health wants to scale while the market window is open.
"This Series D financing validates our strong commercial momentum and differentiated platform, as well as the tremendous market opportunity in early cancer detection," said Dave Mullarkey, chief executive officer of ClearNote Health.
What could go wrong? Early cancer detection is a crowded and capital-intensive space, with heavyweights like Grail (owned by Illumina) and Guardant Health already competing for clinical adoption and reimbursement. Regulatory hurdles, reimbursement challenges, and the need to prove clinical utility in large-scale studies remain significant obstacles for any player in this market.
ClearNote Health is still privately held, meaning it will likely need additional capital to reach profitability — and investor patience in biotech has thinned considerably since the post-pandemic boom.
The signal: ClearNote Health's $52M raise — led by repeat angel backer Mattias Westman — underscores enduring investor conviction in early cancer detection even as broader biotech funding remains constrained. Dealroom classifies the company at the "breakout" growth stage, suggesting it is transitioning from clinical validation to commercial scale, a shift reinforced by the hiring of a seasoned diagnostics operator from Illumina. With liquid biopsy rivals already public and competing for reimbursement, the speed of that commercial ramp will likely determine whether ClearNote Health can carve out a durable position in an increasingly crowded oncology diagnostics market.
Read more: Benzinga
